Skip to main content

BNF for Children February 2023 Update

This update contains 3 significant changes and 1 dose change.

Significant Changes:

  • Dupilumab (Dupixent®): risk of ocular adverse reactions and need for prompt management [MHRA/CHM advice].
  • Ibuprofen: updated breast-feeding advice.
  • Obesity: updated guidance on management.

Dose Change:

  • Crysvita® (burosumab) [update to children’s dosing].